Table 1.
The most important demographic and clinical parameters of the examined patients with acute, chronic heart failure (HF) and the control group. NYHA: New York Heart Association Classification, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin-II receptor blocker, MRA: mineralocorticoid receptor antagonist.
| Acute HF (n = 13) |
Chronic HF (n = 33) |
Control Group (n = 13) |
|
|---|---|---|---|
| Mean age (year) | 66.5 ± 3.7 | 65.9 ± 3.8 | 65.8 ± 4.0 |
| Gender | 33% women 67% men |
34.3% women 65.7% men |
31% women 69% men |
| Mean ejection fraction (%) | 33.1% | 30.3% | 38.5% |
| NYHA stage | III–IV. st. | II. st. | I. st. |
| Cardiovascular status | decompensated | compensated | no heart failure |
| Comorbidities | |||
| Hypertension | 69.2% | 87.9% | 46.1% |
| Diabetes mellitus | 46.2% | 42.4% | 15.4% |
| Atrial fibrillation | 53.8% | 36.4% | 7.7% |
| Medical therapy | |||
| ACEI/ARB | 100% | 100% | 38.5% |
| β-blocker | 100% | 100% | 38.5% |
| MRA | 76.9% | 81.8% | 0% |
| Diuretics | 92.3% | 84.8% | 15.4% |
| Ivabradine | 23.1% | 9.0% | 0% |
| Digoxin | 15.4% | 15.2% | 0% |